Completed PHASE2 INTERVENTIONAL 1-arm NCT01677897

Impact of the Addition of Metformin to Abiraterone in Metastatic Prostate Cancer Patients (MetAb-Pro)

Impact of the Addition of Metformin to Abiraterone in Pre-docetaxel Metastatic Castration-resistant Prostate Cancer Patients Progressing on Abiraterone Treatment (MetAb-Pro): a Phase II Pilot Study

Sponsor: Janssen-Cilag Ltd.

Conditions Metastatic Prostate Cancer

Interventions Metformin

Updated 6 times since 2017 Last updated: Mar 3, 2019 Started: Aug 31, 2013 Primary completion: Dec 31, 2017 Completion: Jun 30, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Metastatic Prostate Cancer and is currently completed. Janssen-Cilag Ltd. leads this study, which shows 6 recorded versions since 2013 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Apr 2019 — Jan 2021 [monthly]

Completed PHASE2

Status: Unknown Status → Completed
Jun 2018 — Apr 2019 [monthly]

Unknown Status PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Aug 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen-Cilag Ltd.
Kantonsspital Graubünden

Data source: Kantonsspital Graubünden

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chur, Switzerland